Avicularin

Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities^[1][3]. IC50 & Target: NF κB (p65)^[2], In Vitro: Avicularin (10-300 μM, 1 h) suppresses NO and PGE₂ production in LPS-stimulated RAW 264.7 cells^[1].
Avicularin (10-300 μM, 1 h) exhibits anti-inflammatory activity through the suppression of ERK signaling pathway in LPS-stimulated RAW 264.7 cells^[1].
Avicularin (25-100 μg/mL, 48 h) decreases cell proliferation, cell migration and invasion in Huh7 cells^[2].
Avicularin (25-100 μg/mL, 48 h) induces apoptosis via the downregulation of NF‑κB (p65) and COX‑2 and the upregulation of PPAR‑γ^[2].
Avicularin (50 μM, 6 days) decreases the intracellular lipids, along with decreased PPARγ, C/EBPα, and aP2 mRNA levels in 3T3-L1 cells^[3].
Avicularin (50 μM, 6 days) suppresses GLUT4-Mediated glucose uptake in 3T3-L1 cells^[3].
Avicularin (2.5-10 μM, 2 h) inhibits ECM degradation and inflammation via TRAF6/MAPK activation in rat and human chondrocytes^[4]. In Vivo: Avicularin (injected in articular cavity of the knee, 0.5-2 mg/kg, twice a week for 4 weeks) attenuates the development of OA (osteoarthritis) in ACLT-induced rats^[4].
Avicularin (oral administration, 50 and 100 mg/kg, for 21 days) attenuates memory Impairment in rats with amyloid Beta-induced Alzheimer's disease^[5].